Consultation: Amending the Food and Drug Regulations to provide expedited access to COVID-19 drugs
From: Health Canada
Current status: Open
Opened on November 30th, 2020, and closed on December 21st, 2020.
The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 introduced new regulatory pathways to expedite the authorization of COVID-19 drugs to meet a public health emergency without compromising patient safety. The interim order (IO) expires on September 16, 2021. To ensure uninterrupted access to these drugs, Health Canada is proposing to amend the Food and Drug Regulations.
Join in: how to participate
Review the proposal
Consultation on amending the Food and Drug Regulations to expedite access to COVID-19 drugs
Send us an email
hc.hpfb-covid19-dgpsa.sc@canada.ca
Who is the focus of this consultation
The Government of Canada will engage with:
- importers
- distributors
- manufacturers
- health system partners
- other stakeholders
Key questions for discussion
Industry plays an important role in facilitating early access to these drugs. Through this consultation, Health Canada wants to make sure key stakeholders:
- are aware of the transition approach we want to take to ensure COVID-19 drugs can continue to be authorized and marketed once the IO expires
- will identify any concerns they have about these proposed measures
Your ideas and input are sought:
- Are there any comments or concerns with the implementation of these measures?
- Have you experienced challenges as it relates to your ability to satisfy division 2 good manufacturing practice (GMP) requirements, either currently or in the early days of the pandemic? If yes:
- what measures would be useful to help you overcome these challenges?
- do you anticipate challenges in satisfying GMP requirements as the pandemic progresses?
- Are there any comments or concerns about the proposed approach to fees for COVID-19 drugs?
The input gathered through this process will help Health Canada’s work on amending the Food and Drug Regulations to ensure that Canadians continue to have access to COVID-19 drugs.
Contact us
Contact us by email: hc.hpfb-covid19-dgpsa.sc@canada.ca
Related links
Report a problem or mistake on this page
- Date modified: